INVESTOR RELATIONS

Scientific Posters and Presentations

Icotrokinra (JNJ-77242113):

For posters and presentations relating to icotrokinra (JNJ-77242113), please refer to the link here (link and site maintained by Johnson & Johnson):

Immunology Congresses

Rusfertide (PTG-300):


June 11, 2026
Benefit of Rusfertide Maintained in Patients (Pts) With Low-Risk or High-Risk Polycythemia Vera (PV): Efficacy and Safety Subgroup Analysis From the Randomized Controlled Phase 3 VERIFY Study
September 3, 2025
Results from VERIFY, An International, Randomized Phase 3 Double-blind Placebo-controlled Study of Rusfertide (First-In-Class Hepcidin Mimetic) for Treatment of Polycythemia Vera (PV)
August 22, 2025
VERIFY, A Phase 3 Placebo-Controlled Study Investigating Rusfertide With Current Standard of Care Therapy in Patients With Polycythemia Vera
May 30, 2025
Adaptation of ASCO’25 Phase 3 VERIFY Plenary Presentation
December 7, 2024
Final Results from the Phase 2 REVIVE Study Investigating the Hepcidin Mimetic Rusfertide in Patients with Polycythemia Vera (PV)
October 24, 2024
Updated Long-Term Results from the Phase 2 REVIVE Study Investigating the Hepcidin Mimetic Rusfertide in Polycythemia Vera Patients: Hematocrit Control and Therapeutic Phlebotomy Frequency
LOAD MORE

DISCOVERY:


December 9, 2023
Iron Restricted Erythropoiesis under Hepcidin Mimetic Treatment (PN23114) Improves Disease Parameters in a Mouse Model for Sickle Cell Disease
December 10, 2022
Rusfertide Analog-PN23114 as a Hepcidin Mimetic Provides Efficacy Benefits in Conjunction with Phlebotomy in Mouse Model for Hereditary Hemochromatosis (Oral Presentation)
December 11, 2021
Regulation of Iron Homeostasis and Efficacy of Rusfertide Analog Peptide in a Mouse Model for Polycythemia Vera

PN-881:


September 17, 2025
PN-881: First-in-class oral peptide targeting the IL-17 pathway
May 7, 2025
PN-881: First-in-class oral peptide targeting the IL-17 pathway

PEER-REVIEWED MANUSCRIPTS

Icotrokinra (JNJ-77242113):


October 14, 2026
Abreu MT, et al. New Engl J Med. 2026; Epub ahead of print.
October 12, 2026
Lebwohl MG, et al. Dermatol Ther (Heidelb). 2026;16(10):5049-5068. Safety of Icotrokinra Through 1 Year for the Treatment of Moderate-to-Severe Plaque Psoriasis and Psoriasis Affecting High-Impact Sites: Pooled Results Across the ICONIC-LEAD, ICONIC-TOTAL, and ICONIC-ADVANCE 1 and 2 Phase 3 Trials.
October 11, 2026
Stein Gold L, et al. Br J Dermatol. 2026;195(4):600. Durability of response to icotrokinra in adults with moderate-to-severe plaque psoriasis: 1-year results from the phase III, placebo- and active comparator-controlled ICONIC-ADVANCE 1 and ICONIC-ADVANCE 2 trials
October 10, 2026
Soung J, et al. J Am Acad Dermatol. 2026;95(4):1109-1112. Maintenance of response with icotrokinra, a targeted oral peptide, for the treatment of moderate-to-severe plaque psoriasis: Randomized treatment withdrawal in adults from the phase 3, ICONIC-LEAD study
October 9, 2026
Warren RB, et al. J Eur Acad Dermatol Venereol. 2026;40(9):1502-1514.
October 8, 2026
Soung J, et al. J Am Acad Dermatol. 2026;95(4):1103-1106. Improvements in clinical and patient-reported outcomes and durability of response with the targeted oral peptide icotrokinra in adolescents with moderate-to-severe plaque psoriasis: One-year results from the ICONIC-LEAD randomized controlled trial
LOAD MORE

Rusfertide (PTG-300):


PN-943:


PTG-100: